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Abstract
Introduction. A search continues for new markers and new monitoring methods that would be useful in the manage-
ment of patients with advanced heart failure (HF). Recent studies have shown increased levels of cancer antigen 125 
(Ca 125) and copeptin in patients with HF which implies that they may be used as markers of HF.
Material and methods. The aim of the study was to evaluate levels of potential HF markers in relation to established 
biochemical markers. The study included 60 patients who were admitted due to exacerbation of chronic New York Heart 
Association class III or IV systolic HF. Before administration of initial intravenous diuretic dose, blood samples were 
collected to determine levels of conventional prognostic factors (uric acid, B-type natriuretic peptide [BNP]) and novel 
HF biomarkers (Ca 125, copeptin).
Results. On admission, BNP level (median 1166.50 pg/mL [636.00–2068.50]) and uric acid level (9.497 ± 2.426 mg/dL) 
in patients with HF was significantly higher compared to respective normal values. Ca 125 level (median 88.71 U/mL 
[29.28–169.00]) was also significantly increased, and copeptin level was significantly higher compared to the control 
group (median 96.55 vs 7.05 pg/mL, p < 0.0001). In additional, a statistically significant correlation between baseline 
BNP and Ca 125 levels (r = 0.48, p < 0.001) was observed. No correlations were found between baseline levels of 
copeptin and BNP or uric acid.
Conclusion. In patients with chronic HF, several pathomechanisms are operating, which may be indicated by increased 
levels of several markers, including both conventional and new ones. Higher levels of Ca 125 were observed in patients 
with acute decompensated HF, even though these patients did not have a malignancy. However, Ca 125 did not exceed 
the prognostic value of BNP due to its low specificity. Despite different pathomechanisms of BNP and Ca 125 level 
elevations, a correlation was found between these markers, which might indicate a complex pathophysiology of HF in 
the studied group.
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and administration of intravenous diuretics. Patients with 
concomitant malignancy, acute and chronic inflammatory 
conditions, and liver or kidney failure (serum transami-
nase levels increased threefold above the upper limit of 
normal values or glomerular filtration rate [GFR] < 30 mL/ 
/min/1.73 m², respectively) were excluded from the study. 
All patients received optimal therapy according to the ESC 
guidelines on the management of acute and chronic HF. 
Blood samples for study measurements were collected on 
the day of admission
Laboratory testing
Plasma BNP level was measured by enzyme immunohisto-
chemistry (AxSYM BNP). Serum Ca 125 level was measured 
by electrochemiluminescence (Elecsys Ca 125 II, manufac-
turer reference levels < 35 U/mL). Serum copeptin level 
was measured by the immunoenzymatic method (ELISA) 
(E90365 Hu, USCN). As no established reference values 
are available for copeptin level, we used a control group 
that included 20 healthy volunteers.
Statistical analysis
Statistical analysis was performed using the Statistica 
v. 9.0 (StatSoft) and the MedCalc v.12.4.0.0 (MedCalc 
Software) software. Differences between the evaluated 
parameters and the upper limit of normal values were 
evaluated using the Student t test for a single sample for 
normally distributed variables or the signed rank Wilcox-
on test for non-normally distributed variables. Relations 
between levels of conventional and new HF markers were 
evaluated using the Spearman rank correlation, and the 
results were expressed graphically using linear regression 
curves. P<0.05 was considered statistically significant.
Results
The mean age in the study group was 63.56 years (range 
35–83 years), and men comprised 93% of the study group. 
Ischemic heart disease was the most common aetiology of 
HF (53%), and 38 patients were in NYHA class IV. Charac-
teristics of the study group are shown in Table 1.
We found significantly higher median serum BNP 
and uric acid levels in patients with HF compared to the 
reference values determined by the test manufacturer 
(Table 2). Median BNP level in patients with HF was more 
than 10-fold higher compared to the upper reference 
limit.
Patients with HF were also found to have significantly 
higher Ca 125 levels compared to the reference values 
determined by the test manufacturer (Table 3). Median 
copeptin level in patients with acute decompensated HF 
was more than 10-fold higher compared to the control 
group, a statistically significant difference (Table 3).
Introduction
Heart failure (HF) is a major clinical and social problem. 
Despite improved treatment, HF is the only cardiovascular 
condition with an increasing prevalence, and the most 
common and costly reason for hospital admission among 
patients above 65 years of age. It has been estimated that 
costs of HF treatment amount for 1 to 2% of national health-
care expenditure, and more than 60% of these costs are 
related to inpatient treatment [1]. Established markers of 
HF include B-type natriuretic peptide (BNP) and N-terminal 
pro-B-type natriuretic peptide (NT-proNBP), and their use in 
clinical practice is recommended in the European Society 
of Cardiology (ESC) and American College of Cardiology/ 
/American Heart Association (ACC/AHA) guidelines. Search 
continues for new substances that would allow more pre-
cise identification of HF patients and effective monitoring of 
the condition. Such potential markers of HF include cancer 
antigen 125 (Ca 125) and copeptin.
Cancer antigen 125 is a glycoprotein from the mucin 
family, coded by a gene on human chromosome 19 and 
produced by serosal endothelial cells in response to fluid 
accumulation and/or cytokine production. Ca 125 is an 
established marker used to detect and monitor ovarian 
cancer. It has been recently shown that Ca 125 level is 
elevated also in patients with HF and correlates with the 
disease severity evaluated both clinically and based on 
haemodynamical and echocardiographic markers [2].
Copeptin is a C-terminal fragment of provasopressin, 
released in equimolar amounts with vasopressin but cha-
racterized by a much longer serum half-life compared to 
vasopressin, and significant stability ex vivo [3]. Seminal 
studies have shown that copeptin may be a predictor of 
survival following an acute coronary syndrome, as the 
vasopressin system is activated following myocardial 
infarction [4], and thus copeptin has been considered 
a potential cardiac biomarker by the National Academy of 
Clinical Biochemistry expert panel.
The aim of the study was to evaluate Ca 125 and co-
peptin levels in relation to established HF marker levels 
(BNP and uric acid) in patients with advanced chronic HF 
(chronic New York Heart Association [NYHA] class II–IV 
systolic HF with the left ventricular ejection fraction of 
< 45% treated for at least 3 months) admitted for acute 
decompensated HF.
Material and methods
The study included 60 patients with advanced HF who 
were admitted to a cardiology unit due to HF exacerbation 
defined as new symptoms or signs (e.g., orthopnoea, 
signs of pulmonary congestion, pleural effusion, ascites, 
peripheral oedema) that required acute hospitalization 
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The evaluated parameters were not related to age and 
gender. As a next step, we evaluated correlation between 
baseline Ca 125 and copeptin levels and BNP and uric acid 
levels. We found a significant positive correlation between 
BNP and Ca 125 levels (r = 0.48, p < 0.001) (Figure 1). 
Baseline copeptin level was not related to conventional 
HF markers.
Discussion
Processes that damage myocardium lead to complex he-
modynamic disturbances, including volume overload and 
activation of the renin-angiotensin-aldosterone system 
and sympathetic system. At the same time, production of 
natriuretic peptides increases as a compensatory mecha-
nism to cardiac overload [5].
In our study, levels of biochemical parameters and 
biomarkers of HF were related to normal values. We found 
significantly higher levels of conventional HF markers such 
Table 1. Study group characteristics
Parameter Value
Age [years]:
• mean (range)
• median (range)
63.56 (35–83)
64 (35–83)
Gender, n [%]:
• men
• women
56 (93)
4 (7)
Aetiology of heart failure, n [%]:
• ischemic heart disease
• dilated cardiomyopathy
• other
32 (53)
24 (40)
4 (7)
Concomitant conditions, n [%]:
• hypertension
• diabetes type 2
• hyperlipidaemia
37 (62)
31 (52)
22 (37)
NYHA functional class, n [%]:
• III
• IV
22 (37)
38 (63)
NYHA — New York Heart Association
Table 2. Conventional heart failure markers in the study group 
compared to the reference values
Parameter Study group Reference 
values
p
N Median (IQR) 
Mean ± SD
BNP  
[pg/mL]
60 1166.50 
(636.0–2068.5)
< 100 < 0.0001
Uric acid 
[mg/dL]
60 9.497 ± 2.426 3–7 < 0.0001
BNP — B-type natriuretic peptide; IQR — interquartile range; SD — standard deviation
Table 3. New biomarkers of heart failure in the study group compared to the reference values
New biomarkers Study group Reference  
values
P
N Median (IQR)
Ca 125  
[U/mL]
60 88.71 
(29.28–169.00)
0–35 < 0.0001
Study group Control group P
N Median (IQR) N Median (IQR)
Copeptin  
[pg/mL]
60 96.55 
(38.85–214.20)
20 7.05 
(6.10–13.85)
< 0.0001
Ca 125 — cancer antigen 125; IQR — interquartile range
Figure 1. Correlation between B-type natriuretic peptide (BNP) 
level (pg/mL) and cancer antigen 125 (Ca 125) level (U/mL) in 
patients with acute decompensated chronic heart failure
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as BNP and uric acid. These findings are expected in pa-
tients with advanced HF who comprised the study group. 
The role of BNP and uric acid has been well established in 
numerous studies in patients with HF. High BNP levels are 
associated with higher NYHA class and worse outcomes 
[6]. BNP is measured as a screening test to identify asymp-
tomatic patients with left ventricular dysfunction and early 
HF [7]. Gack et al. [8] showed that plasma BNP levels in 
patients with HF are very high compared to the normal val-
ues (with more than 10-fold increase in severe HF). Similar 
findings were noted in our study in which the upper limit of 
the reference range for BNP level was 100 pg/mL and me-
dian BNP level in the study group exceeded 1100 pg/mL. 
Hyperuricemia is a common metabolic abnormality in 
patients with HF and may predict mortality independent 
from the severity of cardiac disease. Elevated uric acid 
levels are seen in 50–55% of patients with systolic HF [9]. 
Prospective data from 4912 patients in the Framingham 
Offspring study showed that the incidence of HF was six-
fold higher among subjects in the upper quartile of uric 
acid levels (> 6.3 mg/dL) compared to the lowest quartile 
(< 3.4 mg/dL) [10].
Our study also showed significantly higher serum 
levels of two new markers, Ca 125 and copeptin, in pa-
tients with acute decompensated HF. In the recent years, 
a number of reports were published showing elevated 
Ca 125 levels in HF patients and indicating a possible 
clinical and biological role of Ca 125 in the complex 
disease process of HF [11]. In our study, we showed that 
most patients with acute decompensated NYHA class III 
or IV HF had elevated baseline Ca 125 level (42 of 60 pa-
tients, or 70%). These observations are in agreement with 
previous literature reports. In a group of 286 patients with 
systolic HF, D’Aloia et al. [12] showed that Ca 125 level 
measured on admission was elevated in more than half 
of their subjects (152 of 286, 53%), mostly with moderate 
to severe (84% and 100% of patients in NYHA class III 
and IV, respectively).
Vasopressin is an antidiuretic and vasoconstrictor 
hormone synthesized in the hypothalamus in response 
to increased osmolarity and hypovolemia [13]. One study 
showed that vasopressin level is increased in patients 
with HF and vasopressin may have an important role in 
disease progression [14]. Copeptin is a pre-provasopressin 
fragment synthesized and released in equimolar amounts 
with vasopressin, and its advantages include stability and 
possibility of rapid serum or plasma level determination 
[15]. In our study, we showed that patients with acute 
decompensated HF had more than 10-fold higher median 
copeptin level compared to the control group, a statistically 
significant difference (median 96.5 pg/mL vs. 7.05 pg/mL, 
or 24.0 pmol/L vs. 1.8 pmol/L, p < 0.0001). These find-
ings are similar to other literature data. The upper limit 
of normal copeptin level in healthy subjects was reported 
at 11.25–16.4 pmol/L [3]. Other studies also showed 
an increased copeptin level in patients with HF [16, 17]. 
Miller et al. [16] reported that median copeptin level in 
a study in 187 outpatients with NYHA class III–IV HF was 
16.6 pmol/L (7.3–31.1) [16]. Similarly, in a study by Balling 
et al. [17], median copeptin level in outpatients with NYHA 
class I–IV HF was 15.5 pmol/L (5.60–54.82). In another 
study in 786 patients with NYHA class I–IV HF, mean co-
peptin level was elevated at 18.9 ± 24.2 pmol/L (range 
0.7–224 pmol/L) [18]. Voors et al. [19] studied copeptin 
level in patients 3 days after an acute myocardial infarc-
tion, all with symptoms of HF and a reduced left ventricular 
ejection fraction below 35%. Despite very short duration 
of HF, copeptin levels were already elevated (median 
14 pmol/L, range 8–26 pmol/L). It was also found that 
copeptin level decreased at one year (median 7 pmol/L, 
range 5–11 pmol/L), which may indicate a high sensitivity 
of this diagnostic test.
Our findings indicated a significant positive relation 
between baseline BNP and Ca 125 levels in the study 
group (r = 0.48, p < 0.001). Similar results were reported 
by Duman et al. in patients with NYHA class III–IV HF, in 
whom elevated Ca 125 levels were observed in parallel 
to an increase in norepinephrine and particularly BNP 
levels [20]. Chen et al. showed that in patients with HF, 
BNP and Ca 125 levels were significantly higher com-
pared to subjects without HF, and Ca 125 level showed 
a positive correlation with the left ventricular ejection 
fraction (r = 0.789, p < 0.01), similarly to BNP (r = 0.730, 
p < 0.01) [21]. In another study in 293 patients admitted 
due to acute decompensated HF, the prognostic value of 
BNP and Ca 125 was evaluated. The endpoint included 
death and hospitalization due to exacerbation of HF, 
and the median duration of follow-up was 18 months. 
The authors showed a superior prognostic value of the 
combination of both markers, BNP and Ca 125 [22]. 
Folga et al. [23] showed that elevated NT-proBNP and 
Ca 125 levels are independent predictors of mortality 
in patients with HF.
Available literature data indicate that these two bio-
markers reflect different pathophysiological mechanisms 
associated with exacerbation of HF. The mechanism of 
elevation of serum Ca 125 level in patients with acute 
decompensated HF has not been clearly elucidated. Some 
authors have suggested that it may be related to pleural, 
peritoneal, and pericardial effusion [11]. High Ca 125 lev-
els may be associated with volume overload and inflamma-
tion [24]. Indirect evidence that elevated Ca 125 levels in 
patients with HF are not only related to volume overload 
was provided by the study by D’Aloia et al. who showed 
that an increase in Ca 125 level was seen both in patients 
with effusion and those without effusion [12]. A similar 
relation was reported by Nagele et al. [25]. Another study 
showed a significant relation between Ca 125 level and 
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left ventricular end-diastolic pressure and BNP level, the 
latter being produced mainly in response to increase left 
ventricular wall strain and volume overload [11]. Based on 
these studies, it may be suggested that production of Ca 
125 in patients with HF may have complex aetiology and 
may show relation with increased BNP level. Another ad-
vantage of evaluating both markers may be their different 
pharmacokinetics. BNP has a short half-life (20 minutes) 
while Ca 125 is a stable marker with a half-life of more 
than one week. Based on the above results, it may be 
suggested that Ca 125 reflects changes in volume status 
and inflammation while BN reflects transient hemodynamic 
changes in patients with HF.
No relation was found between baseline copeptin 
levels and conventional markers of HF. Multiple studies 
showing the predictive value of copeptin in patients with 
HF are available in the literature, while few studies evalu-
ated the relation between copeptin and BNP levels. One 
study showed, using logistic regression analysis, a weak 
correlation between copeptin and NT-proBNP levels in 
340 patients with NYHA class III–IV HF [26]. Our finding 
of no relation between copeptin and BNP levels may be 
perhaps explained by a smaller sample evaluated in our 
study compared to the above cited study.
Several limitations of our study should be noted in re-
lation to the available literature data. First, our study was 
smaller than studies reported by other authors. We only 
evaluated patients with severe heart failure (NYHA class 
III–IV). The study group consisted mostly of men, similarly 
to studies by other authors, while registries indicate an 
increasing incidence and prevalence of HF in women [27]. 
In the study by Maedy et al. [28], measurements of HF 
biomarkers at 3 months after hospital discharge had an ad-
ditional prognostic value . In our study, last measurement 
of the study parameters were performed at discharge. 
However, our findings should prompt further studies in 
a larger patient population with a longer follow-up and 
outpatient measurement of biomarker levels.
Conclusions
1. In patients with acute decompensated HF, baseline 
Ca 125 and copeptin levels were significantly elevated 
compared to the reference values and control group, 
respectively. 2. Despite different pathomechanisms of 
BNP and Ca 125 level elevations, a correlation was found 
between these markers, which might indicate a complex 
pathophysiology of HF.
Streszczenie
Wstęp. Wciąż poszukuje się nowych markerów sercowych i nowych metod monitorowania, które mogą być użyteczne 
w terapii chorych z zaawansowaną niewydolnością serca (HF). W ostatnich doniesieniach naukowych wykazano, że 
u pacjentów z HF obserwuje się podwyższone stężenia antygenu nowotworowego 125 (Ca 125) oraz kopeptyny, co może 
sugerować, że substancje te są markerami HF.
Materiał i metody. Celem badania była ocena stężenia potencjalnych markerów HF w odniesieniu do klasycznych, bio-
chemicznych czynników rokowniczych. Do badania włączono 60 pacjentów z zaostrzeniem przewlekłej HF w III i IV klasie 
czynnościowej według New York Heart Association. Przy przyjęciu do szpitala pobierano krew w celu oznaczenia stężeń 
klasycznych czynników rokowniczych (kwas moczowy, peptyd natriuretycznego typu B [BNP]) oraz nowych biomarkerów 
— Ca 125 i kopeptyny.
Wyniki. W badanej grupie wykazano istotnie statystycznie podwyższone stężenia klasycznych markerów HF takich jak 
BNP (Me: 1166,50 pg/ml [636,00–2068,50]) oraz kwas moczowy (X: 9,497 ± 2,426) w stosunku do wartości prawidło-
wych. W przypadku nowych markerów HF stwierdzono, że stężenie Ca 125 w badanej grupie również było istotnie pod-
wyższone w odniesieniu do wartości prawidłowych (Me: 88,71 [29,28–169,00]). Stężenie kopeptyny w badanej grupie 
było istotnie wyższe niż w grupie kontrolnej (Me: 96,55 pg/ml v. 7,05; p < 0,0001). Ponadto zaobserwowano statystycznie 
znamienną współzależność między wyjściowymi stężeniami BNP i Ca 125 (R = 0,48; p < 0,001). Nie wykazano współza-
leżności między wyjściowymi stężeniami kopeptyny a stężeniami klasycznych markerów HF — BNP i kwasu moczowego.
Wnioski. W zaawansowanej HF dochodzi do zaburzeń wielu patomechanizmów, co ma odzwierciedlenie w podwyższo-
nych stężeniach różnych substancji, zarówno klasycznych, jak i nowych markerów HF. Podwyższone wartości Ca 125 
obserwuje się u chorych z ciężką HF mimo braku choroby nowotworowej, jednak Ca 125, ze względu na małą swoistość, 
nie przewyższa prognostycznie wartości stężeń BNP. Mimo odmiennego patomechanizmu stężenia BNP oraz Ca 125 
wykazywały współzależność, co może świadczyć o złożonej patofizjologii HF w badanej grupie.
Słowa kluczowe: niewydolność serca, biomarkery, Ca 125, kopeptyna, BNP
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